Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADL5859 for Pain in Rheumatoid Arthritis
NCT00626275Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Oct 2007
- Primary completion
- Sep 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ADL5859 in rheumatoid arthritis (RA), sponsored by Merck & Co.. Started Oct 2007; status: completed.
02
Drugs
ADL5859
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00626275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626275.